2023 - Research.com Medicine in Italy Leader Award
His primary areas of investigation include Internal medicine, Cardiology, Heart failure, Myocardial infarction and Heart disease. His work carried out in the field of Internal medicine brings together such families of science as Placebo, Endocrinology and Surgery. His Cardiology research is multidisciplinary, relying on both Valsartan, Blood pressure and Prospective cohort study.
Aldo P. Maggioni studies Heart failure, namely Ejection fraction. His Myocardial infarction research incorporates themes from Stroke, Aspirin, Captopril and Risk factor. The concepts of his Heart disease study are interwoven with issues in Candesartan, Electrocardiography in myocardial infarction and Heart rate.
His main research concerns Internal medicine, Cardiology, Heart failure, Myocardial infarction and Ejection fraction. His study in the fields of Atrial fibrillation, Hazard ratio and Randomized controlled trial under the domain of Internal medicine overlaps with other disciplines such as In patient. His Cardiology study incorporates themes from Stroke, Valsartan, Blood pressure and Prospective cohort study.
His Heart failure research incorporates elements of Clinical trial, Intensive care medicine, Placebo, Proportional hazards model and Heart disease. His research on Myocardial infarction frequently connects to adjacent areas such as Surgery. Ejection fraction connects with themes related to Tolvaptan in his study.
The scientist’s investigation covers issues in Internal medicine, Cardiology, Heart failure, Ejection fraction and In patient. As a member of one scientific family, Aldo P. Maggioni mostly works in the field of Internal medicine, focusing on Diabetes mellitus and, on occasion, Disease. His Cardiology research includes elements of Randomized controlled trial and Risk factor.
The Heart failure study which covers Intensive care medicine that intersects with MEDLINE. The Atrial fibrillation study combines topics in areas such as Ablation and Cohort. His work on Myocardial infarction is being expanded to include thematically relevant topics such as Stroke.
Internal medicine, Cardiology, Heart failure, Ejection fraction and Hazard ratio are his primary areas of study. Borrowing concepts from In patient, Aldo P. Maggioni weaves in ideas under Internal medicine. His Cardiology research is multidisciplinary, incorporating elements of Interquartile range, Randomized controlled trial, Disease and Blood pressure.
His Ventricular assist device study in the realm of Heart failure connects with subjects such as Healthcare policy. His biological study spans a wide range of topics, including Cardiomyopathy and Clinical trial. His study in Hazard ratio is interdisciplinary in nature, drawing from both Lower risk, Comorbidity and Renal function.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.
Stamatis Adamopoulos;Stefan D. Anker;Volkmar Falk;Lars Køber.
European Heart Journal (2012)
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
John J.V. McMurray;Stamatis Adamopoulos;Stefan D. Anker;Angelo Auricchio.
European Journal of Heart Failure (2012)
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
Gilles Montalescot;Udo Sechtem;Stephan Achenbach;Felicita Andreotti.
European Heart Journal (2013)
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
Marc A. Pfeffer;John J.V. McMurray;Eric J. Velazquez;Jean-Lucien Rouleau.
The New England Journal of Medicine (2003)
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
Naveed Sattar;David Preiss;Heather M Murray;Paul Welsh.
The Lancet (2010)
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
Nagesh S Anavekar;John J V McMurray;Eric J Velazquez;Scott D Solomon.
The New England Journal of Medicine (2004)
ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.
R Collins;R Peto;M Flather;S Parish.
The Lancet (1995)
The Seattle Heart Failure Model Prediction of Survival in Heart Failure
Wayne C. Levy;Dariush Mozaffarian;David T. Linker;Santosh C. Sutradhar.
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer;Brian L. Claggett;Rafael Diaz;Kenneth Dickstein.
The New England Journal of Medicine (2015)
Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction Time-Course Analysis of the Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione
Roberto Marchioli;Federica Barzi;Elena Bomba;Carmine Chieffo.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: